Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 2Sarcoma 2Other hematologic neoplasm 2Gastrointestinal 2CNS 2Lymphoid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × capmatinib × Gastrointestinal × Clear all
NCT06988475 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡